Hardebeck, Molly C.
Eli Lilly (United States)
2 papers on CoChatORCID 0009-0009-9641-7137
Most cited papers
- Verified
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Johnston, S., Martin, M., Di Leo, A., Im, S.-A., Awada, A., Forrester, T., Frenzel, M., Hardebeck, M. C., Cox, J., Barriga, S., et al. (2019) · npj Breast Cancer
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 685
- Verified
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy
Di Leo, A., O’Shaughnessy, J., Sledge, G. W., Martin, M., Lin, Y., Frenzel, M., Hardebeck, M. C., Smith, I. C., Llombart-Cussac, A., Goetz, M. P., et al. (2018) · npj Breast Cancer
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 66
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free